Clinical Trials

99 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04589845 2026-03-06

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

920 enrolled 1 FDA

Phase 3 Active not recruiting

Solid Tumors

NCT05170204 2026-03-06

HORIZON 1

71 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03994796 2026-03-04

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Phase 2 Suspended

186 enrolled

CNS

Brain Neoplasms, Neoplasm Metastasis

NCT04603807 2026-02-27

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

220 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06528691 2026-02-17

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase 1/2 Active not recruiting

52 enrolled

CNS

Glioma, Central Nervous System Neoplasms

NCT02650401 2025-12-24

STARTRK-NG

69 enrolled 1 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

825 enrolled

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT05396859 2025-10-20

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Phase 1 Active not recruiting

13 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07199959 2025-09-30

Study on the Mechanism of Acquired Resistance of Entrectinib

Recruiting

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Phase 4 Recruiting

800 enrolled

EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2 Active not recruiting

75 enrolled

Head & Neck

Locally Advanced Thyroid Gland Carcinoma

NCT04551495 2024-12-04

ROSALINE

65 enrolled

Carcinoma, Lobular

NCT06694129 2024-11-19

Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

Not yet recruiting

40 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05159245 2024-07-15

FINPROVE

Other hematologic neoplasm

250 enrolled

Hematologic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04817956 2024-02-29

IMPRESS-N

Phase EARLY_PHASE1 Withdrawn

3,000 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04589832 2023-11-22

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Phase 1/2 Terminated

6 enrolled 9 charts

Dermatologic

Uveal Melanoma

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT02097810 2021-06-09

STARTRK-1

Phase 1 Completed

84 enrolled 1 FDA

Locally Advanced Solid Tumors

NCT03961100 2020-09-07

A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.

Phase 1 Completed

31 enrolled 14 charts

Solid Tumor

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Phase 2 Terminated

1 enrolled 7 charts

Dermatologic

Noonan Syndrome 6, Melanoma

NCT03066661 2019-04-26

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

No longer available

Cancers With NTRK, ROS1, or ALK Gene Fusions

NCT03330990 2018-08-21

Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients

Phase 1 Completed

15 enrolled